Acute sensitivity of Ph-like acute lymphoblastic leukemia to the SMAC-mimetic birinapant

Jennifer Richmond[1], Alissa Robbins[1], Kathryn Evans[1], Dominik Beck[2], Raushan T. Kurmasheva[3], Catherine A. Billups[4], Hernan Carol[1], Sue Heatley[5], Rosemary Sutton[1], Glenn M. Marshall[6], Deborah White[5], John Pimanda[2], Peter J. Houghton[3], Malcolm A. Smith[7], and Richard B. Lock[1]

[1]Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Australia, Sydney, Australia

[2]Lowy Cancer Research Centre, UNSW Australia, Sydney, Australia

[3]Greehey Children's Cancer Research Institute, University of Texas Health Science Center San Antonio, San Antonio, Texas

[4]Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee

[5]South Australia Health and Medical Research Institute, Adelaide, South Australia, Australia

[6]Kids Cancer Centre, Sydney Children's Hospital, Randwick, Australia

[7]Cancer Therapy Evaluation Program, NCI, Bethesda, Maryland

SUPPLEMENTAL FIGURE LEGENDS

Supplemental Figure Legends

Figure S1. *In vivo* birinapant efficacy against Ph-like and infant MLL-ALL PDXs. A-C, Individual mouse %huCD45^{+} cells in the peripheral blood (left panels), and Kaplan–Meier curves for EFS (right panels), for PAKRSL, PALJDL, and ALL-10. D-G, Individual mouse %huCD45^{+} cells in the peripheral blood (left panels), and Kaplan–Meier curves for EFS (right panels), for MLL-5, MLL-6, MLL-7, and MLL-14. Vehicle controls, dashed lines; birinapant treated (30 mg/kg), red solid lines.

Figure S2. *In vivo* birinapant efficacy against BCP-ALL PDXs. Individual mouse %huCD45^{+} cells in the peripheral blood (left panels), and Kaplan–Meier curves for EFS (right panels), for 9 BCP-ALL xenografts. Vehicle controls, dashed lines; birinapant treated (30 mg/kg), red solid lines.

Figure S3. Mouse hematology and weights following birinapant treatment. A, Hematology analysis of peripheral blood samples taken from naïve NOD/SCID mice after 3 treatments with 30 mg/kg birinapant. No differences were observed between control and treated mice for the following parameters, red blood cells (RBC), hemoglobin (HGB), hematocrit (HCT), platelets (PLT) and white blood cells (WBC). B, Body weight over time of NOD/SCID mice engrafted with Ph-like BCP-ALL PDXs and treated with 30 mg/kg birinapant.

Figure S4. Network analysis of the birinapant-signature. The 68-gene birinapant-signature was analyzed using the Ingenuity IPA Core Analysis algorithm. Strikingly, the hierarchical network layout algorithm identified TNFRSF1A as the founder node and major regulator of the underlying network.